Published on July 20, 2012 at
1:14 PM · No Comments A study comparing whether endothelial colony-forming
cells (ECFCs) derived from human placenta or those derived from human umbilical
cord blood are more proliferative and better for forming new blood vessels has
found that ECFCs derived from human placenta are more vasculogenic. The study,
carried out by researchers at the Indiana School of Medicine, is published in a
recent issue of Cell Medicine [2(3)] and is freely available on-line at:
http://www.ingentaconnect.com/content/cog/cm. "Circulating ECFCs isolated
from umbilical cord blood and those isolated from human placenta are
phenotypically identical and have equivalent proliferative potential,"
said study lead author Michael P. Murphy, MD of the Indiana University 's
Department of Surgery. "After transplantation, the circulating
placenta-derived ECFCs formed significantly more blood vessels in vivo than the
ECFCs derived from umbilical cord blood, indicating not only that there are
inherent functional differences between resident and circulating ECFC
populations, but that the placenta-derived cells are more vasculogenic." Umbilical
cord blood and the extra-embryonic membranes of placenta are ideal sources of
progenitor cells, said the researchers, because the tissues are discarded as
medical waste and ethical concerns facing embryonic stem cells are avoided. The
quantity of cells that can be derived from placenta, however, is much greater
than the amount that can be derived from umbilical cord blood, making the
placenta the more abundant source.
No comments:
Post a Comment